Old vaccines, new usages, surprisingly effective in solving the century-old problem -Inactivated African Swine Fever Virus vaccine induces safe and efficient immune protection through mucosal immunity

Yang Jinlong,Yang JingXu
2024-12-24
Abstract:Background: African swine fever is among the most devastating viral diseases of pigs. Despite nearly a century of research, there is still no safe and effective vaccine available. The current situation is that either vaccines are safe but not effective, or they are effective but not <a class="link-external link-http" href="http://safe.Findings" rel="external noopener nofollow">this http URL</a>: The ASF vaccine prepared using the inactivation method with propiolactone provided 98.6% protection within 100 days after three intranasal immunizations, spaced 7 days <a class="link-external link-http" href="http://apart.Conclusions" rel="external noopener nofollow">this http URL</a>: An inactivated vaccine made from complete African swine fever virus particles using propiolactone is safe and effective for controlling ASF through mucosal immunity.
Biomolecules
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to solve the key problems in the development of African Swine Fever (ASF) vaccines. Specifically, ASF is a highly destructive viral disease in the pig - farming industry. Despite nearly a century of research, so far no safe and effective vaccines have been developed yet. The current situation is as follows: - **Difficulty in Balancing Safety and Efficacy**: Existing vaccines are either safe but ineffective or effective but with potential safety hazards. Therefore, developing an ASF vaccine that can ensure both safety and high - efficacy protection has become the key to controlling and preventing the spread of the ASF virus. ### Main contributions of the paper This paper proposes an ASF vaccine prepared with β - propiolactone - inactivated whole - virus particles through the mucosal immunization route (such as nasal spray and oral administration), which solves the safety and efficacy problems of existing vaccines. The research results show that this vaccine can significantly reduce the ASFV viral load after multiple mucosal immunizations and finally achieve complete virus clearance, with a protection rate as high as 98.6%. ### Specific methods 1. **Vaccine preparation**: - Use β - propiolactone to treat the ASFV virus suspension to fragment the virus DNA, prevent its replication and restoration of virulence, while maintaining the integrity of the virus envelope proteins and capsid proteins to retain their immunogenicity. 2. **Immunization route**: - Conduct mucosal immunization through nasal spray and oral administration to stimulate the production of a large amount of secretory IgA (SIgA), thereby preventing the virus from further invading at the mucosal sites. 3. **Experimental verification**: - Pigs in the experimental group and the control group were immunized multiple times, and the effectiveness and safety of the vaccine were verified through precise cross - infection experiments. The results showed that the pigs in the experimental group exhibited a significant decrease in viral load and a high survival rate within 100 days, while all the pigs in the control group died. ### Conclusion This study shows that using the β - propiolactone - inactivated ASF vaccine through the mucosal immunization route is a feasible, safe and can - provide - satisfactory - immunoprotection method, providing new ideas and directions for the development of ASF vaccines. --- If you have more questions or need further information, please feel free to let us know!